Advertisement

Journal of Cutaneous Medicine and Surgery

, Volume 9, Issue 6, pp 271–275 | Cite as

Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study

  • Y. PoulinEmail author
  • Y. Pouliot
  • E. Lamiot
  • N. Aattouri
  • S. F. Gauthier
Article

Keywords

Psoriasis Plaque Psoriasis Chronic Plaque Psoriasis PASI Score Sweet Whey 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abstract

Background

XP-828L is a nutraceutical compound obtained by the extraction of a growth factors-enriched protein fraction from bovine milk. XP-828L may improve psoriasis.

Objectives

An open-label study was performed to determine the efficacy, tolerability and safety of XP-828L in the treatment of plaque psoriasis.

Methods

Eleven adult patients with chronic, stable plaque psoriasis on 2% or more of body surface area (BSA) received 5 g of oral XP-828L twice daily for 56 days.

Results

All 11 patients completed the 56 days of treatment. At day 28, 6 of the 11 patients showed a reduction in PASI score. At 56 days, seven subjects had a decrease in PASI score ranging from 9.5% to 81.3%. Eight (8) out of 11 patients agreed to participate in an additional 8-week extension treatment phase. Improvement of psoriasis was maintained during the extension period. No clinically significant adverse events or laboratory abnormalities occurred.

Conclusion

XP-828L may improve psoriasis in patients with mild-to-moderate psoriasis.

Sommaire

Antécédents

XP-828L est un composé nutraceutique obtenu par extraction d’une fraction protéique enrichie en facteurs de croissance à partir du lait bovin. XP-828L pourrait améliorer la condition des patients atteints de psoriasis.

Objectifs

Une étude ouverte a été menée afin de déterminer l’efficacité, la tolérabilité et l’innocuité de XP-828L dans le traitement des plaques de psoriasis.

Méthodes

Onze patients adultes présentant des plaques de psoriasis stables et chroniques sur 2% ou plus de la surface du corps on reçu par voie orale 5 g de XP-828L deux fois par jours pendant 56 jours.

Résultats

Les 11 patients ont tous complété 56 jours de traitement. Au 28e jour, 6 des 11 patients ont montré une réduction du PASI. Au 56e jour, sept patients ont montré une réduction du PASI allant de 9,5% à 81,3%. Huit (8) patients sur 11 ont accepté de participer à un traitement de 8 semaines supplémentaires. L’amélioration de la condition des patients s’est maintenue durant cette période additionnelle. Aucun événement indésirable marquant ou anormalité au niveau des tests de laboratoire n’ont été notés.

Conclusion

XP-828L pourrait améliorer la condition des patients souffrant d’un psoriasis léger à modéré.

Notes

Acknowledgments

This study was sponsored by Advitech inc., Québec, Canada.

References

  1. 1.
    Stern RS Psoriasis. Lancet 1997; 350:349–353PubMedCrossRefGoogle Scholar
  2. 2.
    Lebwohl M Psoriasis. Lancet 2003; 361:1197–1204PubMedCrossRefGoogle Scholar
  3. 3.
    Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257–270PubMedCrossRefGoogle Scholar
  4. 4.
    Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis. 1977–2000: the EDEN survey. J Invest Dermatol 2003; 120:738–741PubMedCrossRefGoogle Scholar
  5. 5.
    Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49:S44–S50PubMedCrossRefGoogle Scholar
  6. 6.
    Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 1993; 238:1812–1816CrossRefGoogle Scholar
  7. 7.
    Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21:495–505PubMedGoogle Scholar
  8. 8.
    Mayser P, Grimm H, Grimminger F. n-3 fatty acids in psoriasis. Br J Nutr 2002; 87 (Suppl 1):S77–S82PubMedCrossRefGoogle Scholar
  9. 9.
    Playford RJ, Macdonald CE, Johnson WS. Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr 2000; 72:5–14PubMedGoogle Scholar
  10. 10.
    Ward PP, Uribe-Luna S, Conneely OM. Lactoferrin and host defence. Biochem Cell Biol 2002; 80:95–102PubMedCrossRefGoogle Scholar
  11. 11.
    Otani H, Hata I. Inhibition of proliferative responses of mouse spleen lymphocytes and rabbit Peyer’s patch cells by bovine milk caseins and their digests. J Dairy Res 1995; 62:339–348PubMedCrossRefGoogle Scholar
  12. 12.
    Gill HS, Doull F, Rutherfurd KJ, et al. Immunoregulatory peptides in bovine milk. The British Journal of Nutrition 2000; 84:S111–S117PubMedGoogle Scholar
  13. 13.
    Korhonen H, Marnila P, Gill HS. Bovine milk antibodies for health. Br J Nutr 2000; 84 (Suppl 1):S135–S146PubMedGoogle Scholar
  14. 14.
    Aattouri N, Gauthier SF, Santure M, et al. Immunosuppressive effect of a milk-derived extract. Immunology 2004; 1–4Google Scholar
  15. 15.
    Langley RG, Ellis N. Evaluating psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Acad Dermatol 2004; 51(4):563–569CrossRefGoogle Scholar
  16. 16.
    Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80, galiximab, in patients with moderate to severe psoriasis. Clinical Immunology 2004; 111:28–37PubMedCrossRefGoogle Scholar
  17. 17.
    Sharma K, McGowan TA. TGF-β in diabetic kidney disease: role of novel signaling pathway. Cytokine Growth Factor Rev 2000; 11:115–123PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Y. Poulin
    • 1
    Email author
  • Y. Pouliot
    • 2
  • E. Lamiot
    • 2
  • N. Aattouri
    • 2
  • S. F. Gauthier
    • 3
  1. 1.Centre de Recherche Dermatologique du Québec métropolitain (CRDQ)QuébecCanada
  2. 2.Advitech inc.QuébecCanada
  3. 3.Institute of Nutraceuticals and Functional FoodsSTELA Dairy Research Center, Université LavalQuébecCanada

Personalised recommendations